Cyclacel Pharmaceuticals
Cyclacel Pharmaceuticals
CYCC
NASDAQ
1.05
USD
228.13%
About
Cyclacel Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing cancer medicines based on cell cycle, transcriptional regulation and mitosis control biology. The transcriptional regulation program is evaluating fadraciclib, a Cyclin-dependent kinase 9 (CDK9) inhibitor, in solid tumors and hematological malignancies.
The epigenetic/anti-mitotic program is evaluating plogosertib, in solid tumors and hematological malignancies. The Company's Plogosertib is a novel, small molecule, selective and potent Polo-like kinase 1 (PLK1) inhibitor, which has demonstrated potent and selective target inhibition (PLK1 IC50 approximately 3 nM) and efficacy in human tumor xenografts at non-toxic doses.
Its translational biology program supports the development of plogosertib in solid tumor and hematological malignancy indications..
Financials Amount (in millions)
Income statement
Balance sheet
Cash flow
Ratios
| Price and Volume | |
|---|---|
| Volume | |
| Ten Day Average Volume | 53.8K |
| Three Month Average Volume | 2.0M |
| High Low | |
| Fifty-Two Week High | 11.343 USD |
| Fifty-Two Week Low | 0.9517 USD |
| Fifty-Two Week High Date | 19 Oct 2023 |
| Fifty-Two Week Low Date | 29 Aug 2024 |
| Price and Volume | |
| Current Price | 1.052 USD |
| Beta | 1 |
| Relative Price Change | |
| Four Week Relative Price Change | -38.53% |
| Thirteen Week Relative Price Change | -62.77% |
| Twenty-Six Week Relative Price Change | -67.01% |
| Fifty-Two Week Relative Price Change | -85.87% |
| Year-to-Date Relative Price Change | -66.73% |
| Price Change | |
| One Day Price Change | 1.15% |
| Thirteen Week Price Change | -60.15% |
| Twenty-Six Week Price Change | -63.72% |
| Five Day Price Change | -13.76% |
| Fifty-Two Week Price Change | -82.29% |
| Year-to-Date Price Change | -60.60% |
| Month-to-Date Price Change | -35.85% |
| Per Share Data | |
|---|---|
| Book Value | |
| Book Value Per Share (Last Fiscal Year) | 0.57324 USD |
| Book Value Per Share (Most Recent Quarter) | 0.5534 USD |
| Tangible Book Value Per Share (Last Fiscal Year) | 0.57324 USD |
| Tangible Book Value Per Share (Most Recent Quarter) | 0.5534 USD |
| EBITD | |
| EBITD Per Share (Trailing Twelve Months) | -10.67882 USD |
| Revenue | |
| Revenue Per Share (Last Fiscal Year) | 0.49364 USD |
| Revenue Per Share (Trailing Twelve Months) | 0.04232 USD |
| Dividend | |
| Dividend Per Share (Last Fiscal Year) | -99999.99 USD |
| Dividend Per Share (Trailing Twelve Months) | 0.15 USD |
| Dividend Per Share (5 Year) | -99999.99 USD |
| Earnings Per Share | |
| Excluding Extraordinary Items (Last Fiscal Year) | -26.74612 USD |
| Excluding Extraordinary Items (Trailing Twelve Months) | -16.13773 USD |
| Normalized (Last Fiscal Year) | -26.74612 USD |
| Basic Excluding Extraordinary Items (Last Fiscal Year) | -26.74612 USD |
| Basic Excluding Extraordinary Items (Trailing Twelve Months) | -16.13773 USD |
| Including Extraordinary Items (Last Fiscal Year) | -26.74612 USD |
| Including Extraordinary Items (Trailing Twelve Months) | -16.13773 USD |
| Cash | |
| Cash Per Share (Last Fiscal Year) | 3.19013 USD |
| Cash Per Share (Most Recent Quarter) | 3.32373 USD |
| Cash Flow Per Share (Last Fiscal Year) | -26.70953 USD |
| Cash Flow Per Share (Trailing Twelve Months) | -9.30436 USD |
| Free Cash Flow Per Share (Trailing Twelve Months) | -6.14383 USD |
| Margins | |
|---|---|
| Cash Flow Revenue | |
| Cash Flow Revenue (5 Year) | -17,622 |
| Cash Flow Revenue (Trailing Twelve Months) | -14,516 |
| Pretax Margin | |
| Pretax Margin (Trailing Twelve Months) | -25,452.50% |
| Pretax Margin (Last Fiscal Year) | -6,083.57% |
| Pretax Margin (5 Year) | -22,144.52% |
| Gross Margin | |
| Gross Margin (Last Fiscal Year) | -99,999.99% |
| Gross Margin (Trailing Twelve Months) | -99,999.99% |
| Gross Margin (5 Year) | -99,999.99% |
| Operating Margin | |
| Operating Margin (Last Fiscal Year) | -6,060.24% |
| Operating Margin (Trailing Twelve Months) | -25,255.00% |
| Operating Margin (5 Year) | -22,944.05% |
| Net Profit Margin | |
| Net Profit Margin (Last Fiscal Year) | -5,370.24% |
| Net Profit Margin (Trailing Twelve Months) | -21,882.50% |
| Net Profit Margin (5 Year) | -18,789.29% |
| Growth | |
|---|---|
| Book Value | |
| Book Value Per Share (5 Year) | -72.53% |
| Tangible Book Value (5 Year) | -47.54% |
| Free Operating Cash Flow | |
| Free Operating Cash Flow (5 Year) | -99,999.99% |
| Revenue | |
| Revenue Change MRQ vs 1 Year Ago | -98.93% |
| Revenue Growth (3 Year) | 22.87% |
| Revenue Change (Trailing Twelve Months) | -78.55% |
| Revenue Per Share Growth | -33.23% |
| Revenue Growth (5 Year) | -99,999.99% |
| Capital Spending Debt | |
| Capital Spending (5 Year) | -31.23% |
| Total Debt (5 Year) | -99,999.99% |
| Dividends | |
| Dividend Growth (3 Year) | -99,999.99% |
| Earnings Per Share | |
| EPS Change MRQ vs 1 Year Ago | 89.04% |
| EPS Change (Trailing Twelve Months) | 43.90% |
| EPS Growth (3 Year) | -99,999.99% |
| EPS Growth (5 Year) | -99,999.99% |
| EBITDA | |
| EBITDA (5 Year) | -99,999.99% |
| EBITDA (5 Year Interim) | -99,999.99% |
| Net Profit Margin | |
| Net Profit Margin Growth (5 Year) | -99,999.99% |
| Valuation | |
|---|---|
| Total Price to Book | |
| Price to Tangible Book (Last Fiscal Year) | 3 |
| Price to Tangible Book (Most Recent Quarter) | 2 |
| Price to Free Cash Flow | |
| Price to Free Cash Per Share (Last Fiscal Year) | -100,000 |
| Price to Free Cash Per Share (Trailing Twelve Months) | -100,000 |
| Net Debt | |
| Net Debt (Most Recent Quarter) | -6,000,000 |
| Net Debt (Last Fiscal Year) | -3,378,000 |
| Price to Sales | |
| Price to Sales (Last Fiscal Year) | 5 |
| Price to Sales (Trailing Twelve Months) | 26 |
| Price to Earnings | |
| PE Excluding Extraordinary Items (Last Fiscal Year) | -100,000 |
| PE Normalized (Last Fiscal Year) | -100,000 |
| PE Basic Excluding Extraordinary Items (Trailing Twelve Months) | -100,000 |
| PE Excluding Extraordinary Items High (Trailing Twelve Months) | -100,000 |
| PE Excluding Extraordinary Items Low (Trailing Twelve Months) | -100,000 |
| PE Including Extraordinary Items (Trailing Twelve Months) | -100,000 |
| Dividends | |
| Dividend Yield (5 Year) | -99,999.99% |
| Dividend Yield | -99,999.99% |
| Current Dividend Yield | 14.26% |
| Price to Book | |
| Price to Book (Last Fiscal Year) | 2 |
| Price to Book (Most Recent Quarter) | 2 |
| Financial Strength | |
|---|---|
| Debt to Equity | |
| Long Term Debt to Equity (Last Fiscal Year) | 0 |
| Long Term Debt to Equity (Most Recent Quarter) | 0 |
| Payout Ratio | |
| Payout Ratio (Last Fiscal Year) | -99,999.99% |
| Payout Ratio (Trailing Twelve Months) | -99,999.99% |
| Quick Ratio | |
| Quick Ratio (Last Fiscal Year) | -100,000 |
| Quick Ratio (Most Recent Quarter) | -100,000 |
| Enterprise Value | |
| Current Enterprise Value to Free Cash Flow (Last Fiscal Year) | -100,000 |
| Current Enterprise Value to Free Cash Flow (Trailing Twelve Months) | -100,000 |
| Current Ratio | |
| Current Ratio (Last Fiscal Year) | 1 |
| Current Ratio (Most Recent Quarter) | 1 |
| Free Cash Flow | |
| Free Cash Flow (Last Fiscal Year) | -16,319,000 |
| Free Cash Flow (Trailing Twelve Months) | -11,613,000 |
| Net Interest Coverage | |
| Net Interest Coverage (Last Fiscal Year) | -172 |
| Net Interest Coverage (Trailing Twelve Months) | -101 |
| Total Debt to Equity | |
| Total Debt to Equity (Last Fiscal Year) | 0 |
| Total Debt to Equity (Most Recent Quarter) | 0 |
| Management Effectiveness | |
|---|---|
| Return on Assets | |
| Return on Assets (Last Fiscal Year) | -122.40% |
| Return on Assets (Trailing Twelve Months) | -142.14% |
| Return on Assets (5 Year) | -57.58% |
| Return on Equity | |
| Return on Equity (Last Fiscal Year) | -216.31% |
| Return on Equity (Trailing Twelve Months) | -331.28% |
| Return on Equity (5 Year) | -75.68% |
| Return on Investment | |
| Return on Investment (Last Fiscal Year) | -212.95% |
| Return on Investment (Trailing Twelve Months) | -327.21% |
| Return on Investment (5 Year) | -69.81% |